TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2026 Aide Memoire is available on the “Investors” page on its website. Q3 2026 Aide Memoire Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of third quarter 2026 results, which are expected to be released on Tuesday, November 3, 2026, at 7:00 a.m. ET, followed

The memo draws on past results, management outlook comments and selected independent data to help investors prepare for Teva’s expected Nov. 3 report.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) insider Brian Savage sold 7,342 shares of the firm

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) Director Roberto Mignone sold 367,600 shares of the business

Brian Savage, Interim Chief Legal Officer, on September 18, 2026, sold 7,342 shares in Teva Pharmace

Teva Pharmaceutical Industries (NYSE:TEVA) Chief Executive Officer Richard Francis said the company has shifted from being viewed primarily as a generics manufacturer toward a biopharmaceutical company with a growing innovative medicines portfolio, while maintaining and expanding its generics operat

Teva Pharmaceutical Industries (NYSE:TEVA) Sets New 1-Year High - Still a Buy?

Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after its U.S. affiliate shared fresh Phase 3 SOLARIS data on investigational olanzapine LAI TEV-749 for adults with schizophrenia. The SOLARIS update follows a strong run for Teva Pharmaceutical Industries, with the share price at US$38.98 and a 7-day share price return of 5.35% building on an 18.7% year-to-date share price gain. A 3-year total shareholder return of about 2.8x and a 5-year total shareholder return of about 3.4x...

Nykredit A S bought a new stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 340,196 shares of the company

Teva Pharmaceutical Industries stock closed at USD 38.98 on September 18, 2026, marking a 36.25 perc